Cytokinetics, Stifel

Stifel Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation
Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 85.04% Upside As of December 23, 2024, the average one-year price target for Cytokinetics is $84.
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a price target of $24. Orthofix Medical shares closed at $18.36 on Tuesday. See how other analysts view this stock.
Cytokinetics initiated with a Buy at Stifel
Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the
Cytokinetics started at buy by Stifel, aficamten highlighted
Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty Pharma (RPRX) and no M&A,
Stifel starts Cytokinetics stock with Buy, $80 target
Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of $80.00. The new coverage comes after a period of instability for the company,
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
STAT9d
Cytokinetics is not looking to be acquired, CEO says
The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.
Cytokinetics Starts Trial For CK-586 In HFpEF
Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
Yahoo Finance6d
Cytokinetics, Incorporated (CYTK)
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...
The Business Journals1mon
Cytokinetics' potential blockbuster heart drug flips to new partner in China
Cytokinetics could make more geography-centric deals as regulators in the United States, Europe and China review the company's potential blockbuster drug for approval. Cytokinetics Inc. has a new ...
Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586
Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...
news.stocktradersdaily1d
(CYTK) Technical Pivots with Risk Controls
Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...
Yahoo Finance9d
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...